Research and development of new radiopharmaceuticals is focused specifically on the synthesis of compounds intended for PET diagnostics. These compounds are labeled with positron radionuclide 18F. In the field of the compounds suitable for SPECT diagnostics, the research and development has focused on compounds labeled with radionuclide 123I.
